[Biosimilars in Inflammatory Bowel Disease (IBD): Experiences and perceptions of german gastroenterologists]. / Biosimilars bei "Chronisch Entzündlichen Darmerkrankungen (CED)": Erfahrungen und Einschätzungen deutscher Gastroenterologen.
Z Gastroenterol
; 55(4): 369-374, 2017 Apr.
Article
en De
| MEDLINE
| ID: mdl-28056484
ABSTRACT
The European Medicines Agency (EMA) recently approved the first anti-TNF-alpha biosimilar for infliximab (CT-P13) (trade names Inflectra® and Remsima®) in Germany. Over the past year, German gastroenterologists gained experience treating IBD-patients with infliximab biosimilars (IFX-biosimilars). To evaluate their experiences and opinions on biosimilars, we conducted a nationwide online survey among German gastroenterologists. Our results are based on the assessment of 449 questionnaires. Although 61â% of the participants had already prescribed IFX-biosimilars, about two thirds of these participating gastroenterologists with IFX-biosimilar prescription stated their experience as based on fewer than 10 IBD-patients treated with IFX-biosimilars. Only 15â% considered themselves to be very experienced with biosimilars. The lower price in comparison to the originator is seen as the most important advantage of biosimilars (71â%). More than two thirds of the survey participants requested specific gastroenterological trials and registries to increase the data available on biosimilars in IBD-patients (68â%).
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Pautas de la Práctica en Medicina
/
Fármacos Gastrointestinales
/
Enfermedades Inflamatorias del Intestino
/
Biosimilares Farmacéuticos
/
Infliximab
/
Gastroenterólogos
Tipo de estudio:
Prognostic_studies
Límite:
Humans
País/Región como asunto:
Europa
Idioma:
De
Revista:
Z Gastroenterol
Año:
2017
Tipo del documento:
Article